Decreasing racial disparity with the combination of ledipasvir–sofosbuvir for the treatment of chronic hepatitis C
Paul H Naylor , Milton Mutchnick Department of Internal Medicine/Gastroenterology, Wayne State University School of Medicine, Detroit, MI, USA Abstract: African Americans (AA) in the US are twice as likely to be infected with hepatitis C virus (HCV) compared to the non-Hispanic-white US pop...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2017
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/e33799ff9bff4dcf848c544283271e16 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:e33799ff9bff4dcf848c544283271e16 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:e33799ff9bff4dcf848c544283271e162021-12-02T06:11:58ZDecreasing racial disparity with the combination of ledipasvir–sofosbuvir for the treatment of chronic hepatitis C1179-1535https://doaj.org/article/e33799ff9bff4dcf848c544283271e162017-03-01T00:00:00Zhttps://www.dovepress.com/decreasing-racial-disparity-with-the-combination-of-ledipasvirndashsof-peer-reviewed-article-HMERhttps://doaj.org/toc/1179-1535Paul H Naylor , Milton Mutchnick Department of Internal Medicine/Gastroenterology, Wayne State University School of Medicine, Detroit, MI, USA Abstract: African Americans (AA) in the US are twice as likely to be infected with hepatitis C virus (HCV) compared to the non-Hispanic-white US population (Cau). They are also more likely to be infected with HCV genotype 1, more likely to develop hepatocellular carcinoma, and, in addition, have a lower response rate to interferon-based therapies. With the increase in response rates reported for combinations of direct-acting antivirals, the possibility that racial disparity would be eliminated by agents that directly inhibit virus replication has become a reality. The objective of this review is to evaluate the literature from clinical studies and retrospective analysis with respect to the response of AA to the most prescribed antiviral combination sofosbuvir plus ledipasvir. While few studies have focused on AA patients, sufficient information is availed from the literature and studies in our predominately AA clinic population to confirm that ledipasvir–sofosbuvir has a similar effectiveness in AA as compared to Cau. Keywords: hepatitis C, African Americans, ledipasvir, sofosbuvir, Harvoni, direct acting antivirals Naylor PHMutchnick MDove Medical PressarticleHepatitis CDirect Acting Anti-viralsAfrican AmericansDiseases of the digestive system. GastroenterologyRC799-869ENHepatic Medicine: Evidence and Research, Vol Volume 9, Pp 13-16 (2017) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Hepatitis C Direct Acting Anti-virals African Americans Diseases of the digestive system. Gastroenterology RC799-869 |
| spellingShingle |
Hepatitis C Direct Acting Anti-virals African Americans Diseases of the digestive system. Gastroenterology RC799-869 Naylor PH Mutchnick M Decreasing racial disparity with the combination of ledipasvir–sofosbuvir for the treatment of chronic hepatitis C |
| description |
Paul H Naylor , Milton Mutchnick Department of Internal Medicine/Gastroenterology, Wayne State University School of Medicine, Detroit, MI, USA Abstract: African Americans (AA) in the US are twice as likely to be infected with hepatitis C virus (HCV) compared to the non-Hispanic-white US population (Cau). They are also more likely to be infected with HCV genotype 1, more likely to develop hepatocellular carcinoma, and, in addition, have a lower response rate to interferon-based therapies. With the increase in response rates reported for combinations of direct-acting antivirals, the possibility that racial disparity would be eliminated by agents that directly inhibit virus replication has become a reality. The objective of this review is to evaluate the literature from clinical studies and retrospective analysis with respect to the response of AA to the most prescribed antiviral combination sofosbuvir plus ledipasvir. While few studies have focused on AA patients, sufficient information is availed from the literature and studies in our predominately AA clinic population to confirm that ledipasvir–sofosbuvir has a similar effectiveness in AA as compared to Cau. Keywords: hepatitis C, African Americans, ledipasvir, sofosbuvir, Harvoni, direct acting antivirals |
| format |
article |
| author |
Naylor PH Mutchnick M |
| author_facet |
Naylor PH Mutchnick M |
| author_sort |
Naylor PH |
| title |
Decreasing racial disparity with the combination of ledipasvir–sofosbuvir for the treatment of chronic hepatitis C |
| title_short |
Decreasing racial disparity with the combination of ledipasvir–sofosbuvir for the treatment of chronic hepatitis C |
| title_full |
Decreasing racial disparity with the combination of ledipasvir–sofosbuvir for the treatment of chronic hepatitis C |
| title_fullStr |
Decreasing racial disparity with the combination of ledipasvir–sofosbuvir for the treatment of chronic hepatitis C |
| title_full_unstemmed |
Decreasing racial disparity with the combination of ledipasvir–sofosbuvir for the treatment of chronic hepatitis C |
| title_sort |
decreasing racial disparity with the combination of ledipasvir–sofosbuvir for the treatment of chronic hepatitis c |
| publisher |
Dove Medical Press |
| publishDate |
2017 |
| url |
https://doaj.org/article/e33799ff9bff4dcf848c544283271e16 |
| work_keys_str_mv |
AT naylorph decreasingracialdisparitywiththecombinationofledipasvirndashsofosbuvirforthetreatmentofchronichepatitisc AT mutchnickm decreasingracialdisparitywiththecombinationofledipasvirndashsofosbuvirforthetreatmentofchronichepatitisc |
| _version_ |
1718400082008604672 |